Sitemap
En
Press Release
Current Location: Home > Press Release > Investment News & Information

CanSinoBio Covid-19 Vaccine Produced in Pakistan

06-08-2021

With the support of CanSino Biologics Inc., a Chinese vaccine company, Pakistan’s the National Institute of Health recently completed the filling of a batch of CanSinoBio Covid-19 vaccine prime fluid and produced more than 120,000 doses of vaccine in total. This is Pakistan’s first localized production of COVID-19 vaccine.


CanSinoBio Covid-19 vaccine is an adenovirus vector vaccine jointly developed by Institute of Military Medicine of Chinese Academy of Military Science and CanSino Biologics Inc., an enterprise from TEDA. The vaccine complete three phases of clinical trial in Pakistan and is the second Chinese COVID-19 vaccine authorized by Pakistan for emergency use.


According to a survey in Pakistan, Chinese vaccines such as CanSinoBio Covid-19 vaccine are favored by Pakistanis because of their safety and effectiveness.

From Mexico to Pakistan, CanSinoBio is transferring COVID-19 vaccine technology to more developing countries and carrying out joint production with them.


TOP
Website Identification Code: 1201160062

Are you sure you want to leave this page?